Xtant Medical Holdings, Inc. (XTNT:NYSEMKT) closed at $0.287 on October 16, 2026, down 5.32% on the day. The stock trades 69.8% below its 52-week high of $0.950 and 6.2% above its 52-week low of $0.270. Over the past year, it lost 59.6%. Xtant Medical Holdings, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -12.86% | -13.12% | -36.29% | -42.66% | -59.62% |
In 252 trading sessions since October 16, 2025, XTNT closed higher on 82 days (33%). Its best day was August 28, 2026 (+15.15%) and its worst was August 11, 2026 (-28.89%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 4 times.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and devices in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC to fill bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company also provides BacFast HD facet stabilization dowels; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; hMatrix dermal scaffold, an acellular matrix made from donated human dermal tissue that is used to replace a patient's damaged tissue; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and sells sports allografts for anterior and pos...
Find more stocks like XTNT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.